Your search history is turned on.
Date: April 23, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID TORONTO, April 23, 2024 -- Revive Therapeutics Ltd. (Revive or the Company) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and ...
Date: April 18, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product TORONTO, April 18, 2024 -- Revive Therapeutics Ltd. (Revive or the Company) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announc...
Date: April 2, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder TORONTO, April 02, 2024 -- Revive Therapeutics Ltd. (Revive or the Company) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Companys clinica...
Date: March 27, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID TORONTO, March 27, 2024 -- Revive Therapeutics Ltd. (Revive or the Company) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has submit...
Date: March 19, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID TORONTO, March 19, 2024 -- Revive Therapeutics Ltd. (Revive or the Company) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the FDA advised the Company to subm...
Date: March 12, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Revive Therapeutics Provides Corporate Update TORONTO, March 12, 2024 -- Revive Therapeutics Ltd. (Revive or the Company) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and it...
Date: February 28, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Microsoft Word - RVV-Q2-CFO-Dec31-2023 1 FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Carmelo Marrelli, Chief Financial Officer of Revive Therapeutics Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Revive Therapeutics Ltd., ...
Microsoft Word - RVV-Q2-CEO-Dec31-2023 1 FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Michael Frank, Chief Executive Officer of Revive Therapeutics Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Revive Therapeutics Ltd., (th...
Management Discussion & Analysis REVIVE THERAPEUTICS LTD. INTERIM MANAGEMENTS DISCUSSION AND ANALYSIS QUARTERLY HIGHLIGHTS FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2023 REVIVE THERAPEUTICS LTD. Interim Managements Discussion & Analysis Quarterly Highlights For the three and six...
170 Q2 2024 - Revive Financial Statements - December 31, 2023 V3.pdf Revive Therapeutics Ltd. Condensed Interim Consolidated Financial Statements Three and Six Months Ended December 31, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited) Notice to Reader The accompanying unaudited condensed interim consolidated financial statements of Revive Therapeutics Ltd. (the "Company"...